Samir Arora

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial

Stefano Del Prato, Steven E. Kahn, Imre Pávó et al. · The Lancet · 2021 · 586 citations

Metabolic Syndrome, Diabetes Management, Cardiovascular Disease +9

Major Factors Influencing Breastfeeding Rates: Mother's Perception of Father's Attitude and Milk Supply

Samir Arora, Cheryl McJunkin, Julie Wehrer et al. · PEDIATRICS · 2000 · 443 citations

Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial

Markus P. Schlaich, M Bellet, Michael A. Weber et al. · The Lancet · 2022 · 206 citations · Full text

Molecular Pharmacology, Hypertension, Resistant Hypertension +9

Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial

Gary T. Ferguson, J. Mark FitzGerald, Eugene R. Bleecker et al. · The Lancet Respiratory Medicine · 2017 · 121 citations

Asthma, Rheumatology, Allergy Medicine +7

Efficacy and Safety of Glycopyrrolate/Formoterol Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Patients With COPD

Fernando J. Martínez, Klaus F. Rabe, Gary T. Ferguson et al. · CHEST Journal · 2016 · 102 citations

Pulmonary Care, Advanced Lung Disease, Pulmonary Medicine +3